Do analysts prefer GOVX or SQZ?

GeoVax Labs presently has a consensus price target of $150.00, suggesting a potential upside of 46,760.36%. Given GeoVax Labs' stronger consensus rating and higher possible upside, equities analysts clearly believe GeoVax Labs is more favorable than SQZ Biotechnologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SQZ Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer VBIO or SQZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SQZ Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer TCRT or SQZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SQZ Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend SQZ or LABT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SQZ Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer SQZ or GNPX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SQZ Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SQZ or GNPX more profitable?

Genprex has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets SQZ Biotechnologies -369.96% -119.83% -59.90% Genprex N/A -163.12% -128.98%

SQZ Biotechnologies (SQZ) Competitors

$0.02 0.00 (0.00%)

As of 10/2/2026

Compare

SQZ vs. GOVX, VBIO, TCRT, LABT, and GNPX

Should you buy SQZ Biotechnologies stock or one of its competitors? SQZ Biotechnologies's main competitors and comparable companies include GeoVax Labs (GOVX), Valion Bio, Inc. Common Stock (VBIO), Alaunos Therapeutics (TCRT), Lakewood-Amedex Biotherapeutics (LABT), and Genprex (GNPX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SQZ Biotechnologies compare to GeoVax Labs?

GeoVax Labs (NASDAQ:GOVX) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

GeoVax Labs has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 0.2% of GeoVax Labs shares are held by insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

GeoVax Labs has a beta of 3.69, meaning that its stock price is 269% more volatile than the broader market. Comparatively, SQZ Biotechnologies has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market.

GeoVax Labs presently has a consensus price target of $150.00, suggesting a potential upside of 46,760.36%. Given GeoVax Labs' stronger consensus rating and higher possible upside, equities analysts clearly believe GeoVax Labs is more favorable than SQZ Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SQZ Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

GeoVax Labs has higher earnings, but lower revenue than SQZ Biotechnologies. GeoVax Labs is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	0.95	-$21.47M	-$11.34	N/A
SQZ Biotechnologies	$18.16M	0.04	-$79.46M	-$2.61	N/A

In the previous week, GeoVax Labs had 1 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 1 mentions for GeoVax Labs and 0 mentions for SQZ Biotechnologies. GeoVax Labs' average media sentiment score of 0.84 beat SQZ Biotechnologies' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Overall Sentiment
GeoVax Labs	Positive
SQZ Biotechnologies	Neutral

Summary

GeoVax Labs beats SQZ Biotechnologies on 9 of the 16 factors compared between the two stocks.

How does SQZ Biotechnologies compare to Valion Bio, Inc. Common Stock?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 1 mentions for Valion Bio, Inc. Common Stock and 0 mentions for SQZ Biotechnologies. Valion Bio, Inc. Common Stock's average media sentiment score of 0.00 equaled SQZ Biotechnologies'average media sentiment score.

Company	Overall Sentiment
Valion Bio, Inc. Common Stock	Neutral
SQZ Biotechnologies	Neutral

Valion Bio, Inc. Common Stock has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, SQZ Biotechnologies has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market.

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are owned by institutional investors. 2.5% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SQZ Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%

Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than SQZ Biotechnologies. Valion Bio, Inc. Common Stock is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780K	2.96	-$8.88M	-$159.25	N/A
SQZ Biotechnologies	$18.16M	0.04	-$79.46M	-$2.61	N/A

Summary

SQZ Biotechnologies beats Valion Bio, Inc. Common Stock on 8 of the 13 factors compared between the two stocks.

How does SQZ Biotechnologies compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Alaunos Therapeutics has a beta of -0.87, meaning that its share price is 187% less volatile than the broader market. Comparatively, SQZ Biotechnologies has a beta of 2.34, meaning that its share price is 134% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SQZ Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Alaunos Therapeutics has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-232.60%	-158.99%
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%

Alaunos Therapeutics has higher earnings, but lower revenue than SQZ Biotechnologies. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$1.91	N/A
SQZ Biotechnologies	$18.16M	0.04	-$79.46M	-$2.61	N/A

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Alaunos Therapeutics' average media sentiment score of 0.00 equaled SQZ Biotechnologies'average media sentiment score.

Company	Overall Sentiment
Alaunos Therapeutics	Neutral
SQZ Biotechnologies	Neutral

Summary

SQZ Biotechnologies beats Alaunos Therapeutics on 6 of the 11 factors compared between the two stocks.

How does SQZ Biotechnologies compare to Lakewood-Amedex Biotherapeutics?

SQZ Biotechnologies (NYSE:SQZ) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Lakewood-Amedex Biotherapeutics has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat SQZ Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SQZ Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

38.5% of SQZ Biotechnologies shares are owned by institutional investors. 16.0% of SQZ Biotechnologies shares are owned by insiders. Comparatively, 5.4% of Lakewood-Amedex Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Lakewood-Amedex Biotherapeutics has lower revenue, but higher earnings than SQZ Biotechnologies. Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SQZ Biotechnologies	$18.16M	0.04	-$79.46M	-$2.61	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	-$3.85M	-$4.75	N/A

In the previous week, Lakewood-Amedex Biotherapeutics had 7 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 7 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for SQZ Biotechnologies. SQZ Biotechnologies' average media sentiment score of 0.00 beat Lakewood-Amedex Biotherapeutics' score of -0.02 indicating that SQZ Biotechnologies is being referred to more favorably in the media.

Company	Overall Sentiment
SQZ Biotechnologies	Neutral
Lakewood-Amedex Biotherapeutics	Neutral

Summary

SQZ Biotechnologies and Lakewood-Amedex Biotherapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does SQZ Biotechnologies compare to Genprex?

SQZ Biotechnologies (NYSE:SQZ) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SQZ Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Genprex has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%
Genprex	N/A	-163.12%	-128.98%

38.5% of SQZ Biotechnologies shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 16.0% of SQZ Biotechnologies shares are held by company insiders. Comparatively, 0.3% of Genprex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Genprex has lower revenue, but higher earnings than SQZ Biotechnologies. Genprex is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SQZ Biotechnologies	$18.16M	0.04	-$79.46M	-$2.61	N/A
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A

SQZ Biotechnologies has a beta of 2.34, indicating that its share price is 134% more volatile than the broader market. Comparatively, Genprex has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

In the previous week, SQZ Biotechnologies' average media sentiment score of 0.00 equaled Genprex'saverage media sentiment score.

Company	Overall Sentiment
SQZ Biotechnologies	Neutral
Genprex	Neutral

Summary

SQZ Biotechnologies beats Genprex on 8 of the 11 factors compared between the two stocks.

Get SQZ Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SQZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SQZ vs. The Competition

Export

Metric	SQZ Biotechnologies	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$708K	$3.85B	$7.15B	$22.78B
Dividend Yield	N/A	3.65%	2.54%	3.73%
P/E Ratio	-0.01	13.00	274.71	27.75
Price / Sales	0.04	1,288.64	656.46	21.39
Price / Cash	N/A	123.39	78.87	38.23
Price / Book	0.01	16.57	10.93	4.64
Net Income	-$79.46M	-$22.66M	$3.51B	$1.08B
7 Day Performance	N/A	-2.97%	-2.00%	-1.06%
1 Month Performance	N/A	-10.82%	-6.19%	-5.60%
1 Year Performance	N/A	19.00%	8.03%	5.09%

SQZ Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SQZ SQZ Biotechnologies	N/A	$0.02 flat	N/A	-14.3%	$708K	$18.16M	N/A	1,620
GOVX GeoVax Labs	2.7116 of 5 stars	$0.33 -5.1%	$150.00 +44,796.7%	-97.8%	$2.59M	$2.49M	N/A	19	Positive News Gap Up
VBIO Valion Bio, Inc. Common Stock	0.4929 of 5 stars	$2.80 -1.1%	N/A	-96.6%	$2.51M	$780K	N/A	10	Gap Down High Trading Volume
TCRT Alaunos Therapeutics	0.4958 of 5 stars	$0.89 -7.6%	N/A	-68.0%	$2.44M	N/A	N/A	1	Gap Down
LABT Lakewood-Amedex Biotherapeutics	0.7397 of 5 stars	$0.96 -3.5%	N/A	N/A	$2.35M	N/A	N/A	5	Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SQZ) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SQZ Biotechnologies (SQZ) Competitors

SQZ vs. GOVX, VBIO, TCRT, LABT, and GNPX

How does SQZ Biotechnologies compare to GeoVax Labs?

Summary

How does SQZ Biotechnologies compare to Valion Bio, Inc. Common Stock?

Summary

How does SQZ Biotechnologies compare to Alaunos Therapeutics?

Summary

How does SQZ Biotechnologies compare to Lakewood-Amedex Biotherapeutics?

Summary

How does SQZ Biotechnologies compare to Genprex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SQZ vs. The Competition

SQZ Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SQZ Biotechnologies (SQZ) Competitors

SQZ vs. GOVX, VBIO, TCRT, LABT, and GNPX

How does SQZ Biotechnologies compare to GeoVax Labs?

Is GOVX or SQZ more profitable?

Do insiders and institutionals have more ownership in GOVX or SQZ?

Which has more volatility & risk, GOVX or SQZ?

Do analysts prefer GOVX or SQZ?

Which has stronger earnings & valuation, GOVX or SQZ?

Does the media favor GOVX or SQZ?

Summary

How does SQZ Biotechnologies compare to Valion Bio, Inc. Common Stock?

Does the media refer more to VBIO or SQZ?

Which has more volatility & risk, VBIO or SQZ?

Do insiders & institutionals have more ownership in VBIO or SQZ?

Do analysts prefer VBIO or SQZ?

Is VBIO or SQZ more profitable?

Which has better earnings & valuation, VBIO or SQZ?

Summary

How does SQZ Biotechnologies compare to Alaunos Therapeutics?

Which has more volatility and risk, TCRT or SQZ?

Do analysts prefer TCRT or SQZ?

Is TCRT or SQZ more profitable?

Which has preferable earnings & valuation, TCRT or SQZ?

Do institutionals & insiders believe in TCRT or SQZ?

Does the media refer more to TCRT or SQZ?

Summary

How does SQZ Biotechnologies compare to Lakewood-Amedex Biotherapeutics?

Is SQZ or LABT more profitable?

Do analysts recommend SQZ or LABT?

Do insiders and institutionals believe in SQZ or LABT?

Which has higher valuation & earnings, SQZ or LABT?

Does the media prefer SQZ or LABT?

Summary

How does SQZ Biotechnologies compare to Genprex?

Do analysts prefer SQZ or GNPX?

Is SQZ or GNPX more profitable?

Do insiders & institutionals hold more shares of SQZ or GNPX?

Which has preferable earnings and valuation, SQZ or GNPX?

Which has more risk & volatility, SQZ or GNPX?

Does the media prefer SQZ or GNPX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SQZ vs. The Competition

SQZ Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools